Conference Coverage

VIDEO: Get comfortable with screening for, treating CVD risk in RA


 

EXPERT ANALYSIS FROM THE ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES

References

LAS VEGAS – When genetic risk and lifestyle risk factors collide with the baseline systemic inflammation of rheumatoid arthritis (RA), cardiovascular risk increases significantly. Helping patients to manage risk for cardiovascular disease (CVD) requires getting comfortable in making risk assessments and counseling patients about medication and lifestyle options, especially for patients who are not actively being managed by primary care physicians.

Jon Giles, MD, said that a large portion of the elevated risk for CVD in patients with RA is “driven by the fact that [RA] patients have more atherosclerosis.”

Dr. Giles, professor of medicine at Columbia University, New York, said that other CVD risk factors can boost the risk further. “If you have diabetes, smoking, high blood pressure, elevated lipids in your blood – if you have a combination of those plus inflammation, it makes that risk even higher,” Dr. Giles said at the annual Perspectives in Rheumatic Diseases held by Global Academy for Medical Education.

“There’s definitely a lot of data that suggests that, as rheumatologists, we’re not doing a very good job of screening and treating for cardiovascular disease and risk,” Dr. Giles said in an interview at the meeting. He suggests that his fellow rheumatologists become comfortable with screening and treatment guidelines for cardiovascular disease. For selected patients, coronary CT or carotid ultrasound may be valuable in guiding decision making, since very low LDL cholesterol may be correlated with an increased risk of CVD for some patients with RA.

Global Academy for Medical Education and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

koakes@frontlinemedcom.com

On Twitter @karioakes

Recommended Reading

RA patients report worse symptoms at diagnosis, despite earlier presentation
MDedge Rheumatology
IPF Patient Registry will expand
MDedge Rheumatology
Hemophilia carriers are at risk for abnormal bleeding
MDedge Rheumatology
Biosimilar version of etanercept gains FDA approval
MDedge Rheumatology
Lowering LDL-C yields usual benefits in rheumatoid arthritis
MDedge Rheumatology
Simtuzumab did not help IPF patients
MDedge Rheumatology
Try non-TNF biologics for RA if anti-TNF fails
MDedge Rheumatology
VIDEO: Consider chikungunya for unexplained seronegative arthritis
MDedge Rheumatology
VIDEO: Consider immunogenicity when choosing biologics
MDedge Rheumatology
FDA approves biosimilar adalimumab
MDedge Rheumatology